AARD - NASDAQ
Aardvark Therapeutics, Inc. Common Stock
$3.81
-4.5%Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
At a Glance
Live SnapshotAardvark Therapeutics, Inc. Common Stock Street Expectations Map
Wall Street analysts project that AARD stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 22.75, with estimates ranging from a low of 3.00 to a high of 47.00.
The consensus 1-year price target stands at 22.75, with estimates ranging from a low of 3.00 to a high of 47.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Aardvark Therapeutics, Inc. Common Stock Forward Estimates of Revenue
Forward Growth Analysis
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Aardvark Therapeutics, Inc. Common Stock Forward Estimates of Net Income
Forward Growth Analysis
Solid growth trajectory indicates healthy business performance and competitive positioning.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Generally favorable outlook with reasonable growth prospects and analyst support.
Key Insight
High forecast uncertainty: Wide estimate range indicates analysts struggling to predict outcomes—suggests elevated risk and potential volatility.
Aardvark Therapeutics, Inc. Common Stock Forward Estimates of EPS
Forward Growth Analysis
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Key Insight
Declining estimates with wide disagreement: Analysts projecting contraction without consensus signals significant business uncertainty—exercise caution.
Aardvark Therapeutics, Inc. Common Stock Forward Estimates of EBIT
Forward Growth Analysis
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Generally favorable outlook with reasonable growth prospects and analyst support.
Aardvark Therapeutics, Inc. Common Stock Forward Estimates of EBITDA
Forward Growth Analysis
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Generally favorable outlook with reasonable growth prospects and analyst support.
Aardvark Therapeutics, Inc. Common Stock Forward Estimates of SG&A Expense
Forward Growth Analysis
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Aardvark Therapeutics, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $13.87M and sold $78K worth of AARD shares, resulting in $13.79M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
10.0K
144.59K
0
0.00
+145K
+$145K
6-9 Months
33.8K
276.21K
1.2K
5.21K
+271K
+$271K
9-12 Months
1.2M
13.45M
17.2K
72.97K
+13.4M
+$13.38M
Top Buyers
Lee Tien-Li
Director, 10 Percent Owner, Officer: Chief Executive Officer
$6.53M
Sun Nelson
Officer: Chief Financial Officer
$2.46M
Jaiman Manasi
Officer: Chief Medical Officer
$1.43M
Jones Bryan
Officer: Chief Operating Officer
$1.38M
Tong Victor Edward Jr
Director
$689K
Top Sellers
Lee Tien-Li
Director, 10 Percent Owner, Officer: Chief Executive Officer
$78K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $13.79M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
Related Guides
Continue your AARD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.